https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-08 20:19:312021-09-09 15:22:13Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-08 19:56:432021-09-09 15:22:19Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00neilhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgneil2020-06-02 11:11:022021-09-09 15:22:24Press Release: Leading Drug Innovator Reorganizes into Two Separate Companies
The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2020-01-23 20:58:432021-09-09 15:22:29Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee
Propella Therapeutics, Inc. presented “A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)” at the Annual Meeting of the American College of Rheumatology in Atlanta, GA on November 12, 2019.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00neilhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgneil2019-11-12 19:45:002022-09-12 13:09:17Presentation at the Annual Meeting of the American College of Rheumatology (November 12, 2019; Atlanta, GA): A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
Press Release: Leading Drug Innovator Reorganizes into Two Separate Companies
Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.
Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee
The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.
Well-Tolerated Topical Capsaicin Formulation Reduces Knee OA Pain
News coverage of our CGS-200-5 Phase 2 results for OA pain of the knee. Read Article
Presentation at the Annual Meeting of the American College of Rheumatology (November 12, 2019; Atlanta, GA): A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
Propella Therapeutics, Inc. presented “A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)” at the Annual Meeting of the American College of Rheumatology in Atlanta, GA on November 12, 2019.